Transaction Overview
Sinomab BioScience Limited (Stock code: 3681.HK) successfully listed on the Hong Kong Stock Exchange on November 12, 2019. CMBI acted as Joint Bookrunner and Joint Lead Manager for this IPO.
Sinomab is the global leader in innovative therapies for autoimmune diseases and a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. The company strives to become a leading global biopharmaceutical company for the development of novel drugs to fulfill unmet medical needs through its Hong Kong-based R&D and PRC-based manufacturing capabilities. SM03, the company’s flagship product, is a global first-in-target mAb for the treatment of RA and potentially for the treatment of other immunological diseases. As an industry pioneer in the Greater China Region, the company has built and continue to expand its robust product portfolio. As of the Latest Practicable Date, we had a product portfolio of two drug candidates in varying clinical trial stages for the treatment of multiple immunological diseases, and four candidates in the IND-enabling stage.
Sinomab issued 182,129,400 shares (assuming the Over-allotment Option is not exercised). The offering price was set at HK$7.60, and the offering amount was approximately HK$1,384.2 million (assuming the Over-allotment Option is not exercised). The offering has been widely recognized by international and domestic investors, and over-subscribed in International Offering. The investment from cornerstone investors, including Yunnan Baiyao Group Co., Ltd and Reach Software (Hongkong) Limited, represented approximately 34.00% of the total offer size.
Acting as the Joint Bookrunner and Joint Lead Manager, CMBI has fully leveraged the advantages for Chinese investors and high net worth customers, CMBI made positive contributions in investor introduction and marketing, laying a solid foundation for the successful listing of Sinomab.
Source: Company Announcement
About Sinomab
Sinomab is the global leader in innovative therapies for autoimmune diseases and a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, primarily mAb-based biologics. The company strives to become a leading global biopharmaceutical company for the development of novel drugs to fulfill unmet medical needs through its Hong Kong-based R&D and PRC-based manufacturing capabilities. The company has been dedicated to R&D since our inception, and has built a robust pipeline of complementary mAb-based biologics and new chemical entities (NCE) addressing indications against a plethora of immunological diseases. SM03, the company’s flagship product, is a global first-in-target mAb for the treatment of RA and potentially for the treatment of other immunological diseases. Under the leadership of the company’s management team, consisting of members with rich experience in scientific research and business management, the company has established a business model that integrates elements from the entire industry chain encompassing R&D, clinical trials and production. Pursuant to this business model, the company leverages its proven ability in novel drug discovery, clinical development and in-house manufacturing capabilities to enable multiple clinical trials and subsequent commercialization. The company’s vision is to become a global leader in the innovation of therapeutics for immunological diseases.
As an industry pioneer in the Greater China Region, the company has built and continue to expand its robust product portfolio. As of the Latest Practicable Date, we had a product portfolio of two drug candidates in varying clinical trial stages for the treatment of multiple immunological diseases, and four candidates in the IND-enabling stage. These drug candidates target rheumatoid arthritis (“RA”), systemic lupus erythematosus (“SLE”), asthma, pemphigus, Sjogren’s syndrome (“SS”) and other immunological diseases.
The company has a production base in Haikou, Hainan. The company is also constructing commercial-scale production facilities in Suzhou, Jiangsu as part of its commercialization plan. The company’s research center and headquarter are located at the Hong Kong Science Park.
Source: Prospectus
